Strategic partnerships Nemera's expansion activity and recent collaborations with SCHOTT Pharma and Therakind indicate a strong openness to integrated solutions and co-development. This suggests opportunities for joint solution selling, where Nemera’s device platforms are paired with partner capabilities to address integrated drug delivery systems for pharma customers.

European expansion Multiple facility expansions in France and Poland signal ongoing capacity growth in Europe. This creates sales avenues for local procurement of devices and manufacturing services, as well as opportunities to upsell adjacent drug delivery components and contract manufacturing services to regional pharma players.

Dry powder focus The DriDose dry powder intranasal technology development positions Nemera in a high-growth, needle-free delivery niche. Target customers include pharma innovators seeking advanced intranasal delivery, enabling cross-sell of compatible actuation systems and device integration for dry powder therapies.

Diversified delivery platforms Nemera covers ophthalmic, nasal, inhalation, dermal/transdermal, and parenteral devices. This breadth allows cross-sell of end-to-end device solutions to pharma companies pursuing multi-route formulations, as well as opportunities to be the single supplier for multiple patient care delivery needs.

Quality and scale With a focus on high-quality manufacturing and patient-centric design, alongside growing production facilities, Nemera is well positioned to win contracts from mid- to large-cap pharma seeking reliable, compliant device partners for marketable devices and rapid scale-up.